TDMS Study 05121-07 Pathology Tables
NTP Experiment-Test: 05121-07 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05
Study Type: CHRONIC SCOPOLAMINE HYDROBROMIDE TRIHYDRATE Date: 04/03/96
Route: GAVAGE Time: 22:04:19
Facility: Battelle Columbus Laboratory
Chemical CAS #: 6533-68-2
Lock Date: 06/01/92
Cage Range: All
Reasons For Removal: All
Removal Date Range: All
Treatment Groups: Include All
a Number of animals examined microscopically at site and number of animals with lesion
Page 1
NTP Experiment-Test: 05121-07 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05
Study Type: CHRONIC SCOPOLAMINE HYDROBROMIDE TRIHYDRATE Date: 04/03/96
Route: GAVAGE Time: 22:04:19
____________________________________________________________________________________________________________________________________
B6C3F1 MICE FEMALE 0 MG/KG 0 MG/KG 1 MG/KG 5 MG/KG 25 MG/KG
FEED RTD
____________________________________________________________________________________________________________________________________
DISPOSITION SUMMARY
Animals Initially in Study 70 60 70 70 70
Scheduled Sacrifice 10 10 10 10 10
Early Deaths
Natural Death 7 3 3 5 6
Moribund Sacrifice 9 10 11 7 7
Dosing Accident 2 1 1
Survivors
Terminal Sacrifice 33 36 36 37 38
Animals Examined Microscopically 61 60 60 60 61
____________________________________________________________________________________________________________________________________
ALIMENTARY SYSTEM
Gallbladder (61) (60) (59) (59) (61)
Intestine Large, Rectum (61) (60) (60) (60) (60)
Anus, Sarcoma 1 (2%)
Intestine Small, Duodenum (61) (60) (59) (60) (61)
Hemangiosarcoma 1 (2%)
Intestine Small, Jejunum (61) (58) (59) (60) (60)
Carcinoma 1 (2%)
Liver (61) (60) (60) (60) (61)
Hemangiosarcoma 1 (2%)
Hemangiosarcoma, Multiple 1 (2%)
Hepatocellular Carcinoma 7 (11%) 2 (3%) 5 (8%) 5 (8%) 4 (7%)
Hepatocellular Carcinoma, Multiple 1 (2%) 1 (2%) 3 (5%)
Hepatocellular Adenoma 11 (18%) 7 (12%) 13 (22%) 9 (15%) 4 (7%)
Hepatocellular Adenoma, Multiple 5 (8%) 5 (8%) 2 (3%)
Hepatocholangiocarcinoma 1 (2%)
Histiocytic Sarcoma 1 (2%) 3 (5%) 2 (3%) 1 (2%)
Bile Duct, Carcinoma 1 (2%)
Mesentery (7) (5) (9) (4) (5)
Carcinoma, Metastatic, Liver 1 (14%)
Histiocytic Sarcoma 1 (20%) 1 (20%)
Lipoma 1 (20%)
Pancreas (61) (60) (60) (60) (61)
Carcinoma, Metastatic, Liver 1 (2%)
Histiocytic Sarcoma 1 (2%)
Salivary Glands (60) (60) (60) (60) (61)
Stomach, Forestomach (61) (60) (60) (60) (61)
Mast Cell Tumor Benign 1 (2%)
Squamous Cell Papilloma 1 (2%) 1 (2%) 2 (3%)
Stomach, Glandular (61) (60) (60) (60) (61)
Tongue (1)
Page 2
NTP Experiment-Test: 05121-07 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05
Study Type: CHRONIC SCOPOLAMINE HYDROBROMIDE TRIHYDRATE Date: 04/03/96
Route: GAVAGE Time: 22:04:19
____________________________________________________________________________________________________________________________________
B6C3F1 MICE FEMALE 0 MG/KG 0 MG/KG 1 MG/KG 5 MG/KG 25 MG/KG
FEED RTD
____________________________________________________________________________________________________________________________________
ALIMENTARY SYSTEM - cont
Squamous Cell Carcinoma 1 (100%)
____________________________________________________________________________________________________________________________________
CARDIOVASCULAR SYSTEM
Heart (61) (60) (60) (60) (61)
Carcinoma, Metastatic, Liver 1 (2%)
Hepatocholangiocarcinoma, Metastatic, Liver 1 (2%)
____________________________________________________________________________________________________________________________________
ENDOCRINE SYSTEM
Adrenal Cortex (61) (60) (60) (60) (61)
Capsule, Adenoma 1 (2%)
Adrenal Medulla (61) (58) (59) (59) (60)
Pheochromocytoma Malignant 1 (2%)
Pheochromocytoma Benign 2 (3%)
Islets, Pancreatic (61) (60) (60) (60) (61)
Adenoma 1 (2%) 1 (2%)
Pituitary Gland (60) (58) (57) (57) (56)
Pars Distalis, Adenoma 4 (7%) 1 (2%) 3 (5%) 3 (5%) 3 (5%)
Pars Intermedia, Adenoma 1 (2%) 1 (2%)
Thyroid Gland (61) (60) (59) (60) (61)
Follicular Cell, Adenoma 3 (5%) 1 (2%) 3 (5%)
____________________________________________________________________________________________________________________________________
GENERAL BODY SYSTEM
None
____________________________________________________________________________________________________________________________________
GENITAL SYSTEM
Ovary (61) (59) (59) (59) (61)
Cystadenoma 4 (7%) 3 (5%) 1 (2%)
Fibroma 1 (2%)
Hemangiosarcoma 1 (2%)
Histiocytic Sarcoma 2 (3%)
Luteoma 1 (2%)
Uterus (61) (60) (60) (60) (61)
Adenoma 1 (2%)
Hemangioma 1 (2%)
Hemangiosarcoma 1 (2%) 1 (2%)
Hemangiosarcoma, Metastatic, Ovary 1 (2%)
Histiocytic Sarcoma 2 (3%)
Neoplasm NOS 1 (2%)
Polyp Stromal 1 (2%) 1 (2%)
Page 3
NTP Experiment-Test: 05121-07 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05
Study Type: CHRONIC SCOPOLAMINE HYDROBROMIDE TRIHYDRATE Date: 04/03/96
Route: GAVAGE Time: 22:04:19
____________________________________________________________________________________________________________________________________
B6C3F1 MICE FEMALE 0 MG/KG 0 MG/KG 1 MG/KG 5 MG/KG 25 MG/KG
FEED RTD
____________________________________________________________________________________________________________________________________
GENITAL SYSTEM - cont
Sarcoma Stromal 1 (2%) 1 (2%)
____________________________________________________________________________________________________________________________________
HEMATOPOIETIC SYSTEM
Bone Marrow (61) (60) (60) (60) (61)
Hemangiosarcoma 1 (2%)
Histiocytic Sarcoma 1 (2%) 1 (2%)
Lymph Node (6) (3) (5) (4) (3)
Bronchial, Carcinoma, Metastatic, Harderian
Gland 1 (25%)
Bronchial, Carcinoma, Metastatic, Liver 1 (17%)
Bronchial, Hepatocholangiocarcinoma,
Metastatic, Liver 1 (17%)
Bronchial, Histiocytic Sarcoma 1 (33%)
Mediastinal, Carcinoma, Metastatic, Liver 1 (17%)
Mediastinal, Hepatocholangiocarcinoma,
Metastatic, Liver 1 (17%)
Mediastinal, Histiocytic Sarcoma 1 (17%) 1 (33%) 1 (33%)
Lymph Node, Mandibular (59) (57) (55) (58) (61)
Histiocytic Sarcoma 1 (2%)
Lymph Node, Mesenteric (60) (57) (56) (59) (58)
Histiocytic Sarcoma 1 (2%)
Spleen (61) (60) (60) (60) (61)
Hemangiosarcoma 1 (2%) 1 (2%)
Histiocytic Sarcoma 1 (2%) 1 (2%) 1 (2%) 1 (2%)
Thymus (57) (53) (53) (56) (55)
Hepatocholangiocarcinoma, Metastatic, Liver 1 (2%)
Histiocytic Sarcoma 1 (2%) 1 (2%)
Mast Cell Tumor Malignant 1 (2%)
Mediastinum, Rhabdomyosarcoma, Metastatic,
Skeletal Muscle 1 (2%)
____________________________________________________________________________________________________________________________________
INTEGUMENTARY SYSTEM
Skin (61) (60) (60) (60) (61)
Squamous Cell Carcinoma 1 (2%)
Subcutaneous Tissue, Fibrosarcoma 1 (2%) 1 (2%) 1 (2%)
Subcutaneous Tissue, Hemangiosarcoma 1 (2%)
____________________________________________________________________________________________________________________________________
Page 4
NTP Experiment-Test: 05121-07 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05
Study Type: CHRONIC SCOPOLAMINE HYDROBROMIDE TRIHYDRATE Date: 04/03/96
Route: GAVAGE Time: 22:04:19
____________________________________________________________________________________________________________________________________
B6C3F1 MICE FEMALE 0 MG/KG 0 MG/KG 1 MG/KG 5 MG/KG 25 MG/KG
FEED RTD
____________________________________________________________________________________________________________________________________
MUSCULOSKELETAL SYSTEM
Bone (61) (60) (60) (60) (61)
Hepatocholangiocarcinoma, Metastatic, Liver 1 (2%)
Skeletal Muscle (1) (1)
Hepatocholangiocarcinoma, Metastatic, Liver 1 (100%)
Rhabdomyosarcoma 1 (100%)
____________________________________________________________________________________________________________________________________
NERVOUS SYSTEM
Brain (61) (60) (60) (60) (61)
____________________________________________________________________________________________________________________________________
RESPIRATORY SYSTEM
Lung (61) (60) (60) (60) (61)
Alveolar/Bronchiolar Adenoma 3 (5%) 2 (3%) 4 (7%) 1 (2%) 2 (3%)
Alveolar/Bronchiolar Carcinoma 1 (2%) 1 (2%) 3 (5%) 1 (2%) 1 (2%)
Carcinoma, Metastatic, Harderian Gland 1 (2%) 1 (2%)
Carcinoma, Metastatic, Liver 1 (2%)
Hemangiosarcoma, Metastatic, Ovary 1 (2%)
Hepatocellular Carcinoma, Metastatic, Liver 1 (2%) 2 (3%) 5 (8%) 1 (2%)
Hepatocholangiocarcinoma, Metastatic, Liver 1 (2%)
Histiocytic Sarcoma 1 (2%) 2 (3%)
Mediastinum, Hemangiosarcoma 1 (2%)
Nose (61) (60) (60) (60) (61)
Histiocytic Sarcoma 1 (2%)
____________________________________________________________________________________________________________________________________
SPECIAL SENSES SYSTEM
Harderian Gland (18) (10) (15) (16) (16)
Adenoma 1 (6%) 3 (30%) 3 (20%) 2 (13%) 1 (6%)
Carcinoma 2 (11%) 1 (7%) 1 (6%)
____________________________________________________________________________________________________________________________________
URINARY SYSTEM
Kidney (61) (60) (60) (60) (61)
Carcinoma, Metastatic, Liver 1 (2%)
Hepatocholangiocarcinoma, Metastatic, Liver 1 (2%)
Histiocytic Sarcoma 1 (2%) 1 (2%)
Urinary Bladder (60) (60) (58) (59) (61)
Page 5
NTP Experiment-Test: 05121-07 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05
Study Type: CHRONIC SCOPOLAMINE HYDROBROMIDE TRIHYDRATE Date: 04/03/96
Route: GAVAGE Time: 22:04:19
____________________________________________________________________________________________________________________________________
B6C3F1 MICE FEMALE 0 MG/KG 0 MG/KG 1 MG/KG 5 MG/KG 25 MG/KG
FEED RTD
____________________________________________________________________________________________________________________________________
SYSTEMIC LESIONS
Multiple Organs *(61) *(60) *(60) *(60) *(61)
Histiocytic Sarcoma 1 (2%) 4 (7%) 2 (3%) 1 (2%)
Lymphoma Malignant Lymphocytic 2 (3%) 1 (2%) 3 (5%) 2 (3%) 4 (7%)
Lymphoma Malignant Mixed 7 (11%) 5 (8%) 5 (8%) 6 (10%) 3 (5%)
Lymphoma Malignant Undifferentiated Cell 1 (2%)
____________________________________________________________________________________________________________________________________
* Number of animals with any tissue examined microscopically
Page 6
NTP Experiment-Test: 05121-07 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05
Study Type: CHRONIC SCOPOLAMINE HYDROBROMIDE TRIHYDRATE Date: 04/03/96
Route: GAVAGE Time: 22:04:19
____________________________________________________________________________________________________________________________________
B6C3F1 MICE FEMALE 0 MG/KG 0 MG/KG 1 MG/KG 5 MG/KG 25 MG/KG
FEED RTD
____________________________________________________________________________________________________________________________________
TUMOR SUMMARY
Total Animals with Primary Neoplasms (b) 41 28 36 35 30
Total Primary Neoplasms 64 35 58 45 36
Total Animals with Benign Neoplasms 25 14 25 21 19
Total Benign Neoplasms 33 17 34 22 20
Total Animals with Malignant Neoplasms 26 16 22 21 14
Total Malignant Neoplasms 31 17 24 23 16
Total Animals with Metastatic Neoplasms 5 2 7 1
Total Metastatic Neoplasm 19 2 8 1
Total Animals with Malignant Neoplasms
Uncertain Primary Site
Total Animals with Neoplasms Uncertain-
Benign or Malignant 1
Total Uncertain Neoplasms 1
____________________________________________________________________________________________________________________________________
a Number of animals examined microscopically at site and number of animals with lesion
b Primary tumors: all tumors except metastatic tumors
Page 7
NTP Experiment-Test: 05121-07 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05
Study Type: CHRONIC SCOPOLAMINE HYDROBROMIDE TRIHYDRATE Date: 04/03/96
Route: GAVAGE Time: 22:04:19
____________________________________________________________________________________________________________________________________
B6C3F1 MICE MALE 0 MG/KG 0 MG/KG 1 MG/KG 5 MG/KG 25 MG/KG
FEED RTD
____________________________________________________________________________________________________________________________________
DISPOSITION SUMMARY
Animals Initially in Study 70 60 70 70 70
Scheduled Sacrifice 10 10 10 10 10
Early Deaths
Natural Death 6 6 4 5 2
Moribund Sacrifice 4 2 7 4 7
Dosing Accident 1 1
Accidently Killed 2 1
Survivors
Terminal Sacrifice 40 41 39 39 39
Animals Examined Microscopically 60 60 60 60 60
____________________________________________________________________________________________________________________________________
ALIMENTARY SYSTEM
Intestine Small, Duodenum (60) (60) (60) (60) (60)
Adenoma 1 (2%)
Intestine Small, Jejunum (60) (60) (60) (59) (60)
Carcinoma 1 (2%)
Intestine Small, Ileum (59) (60) (59) (60) (58)
Liver (60) (60) (60) (60) (60)
Carcinoma, Multiple 1 (2%)
Hemangioma 1 (2%)
Hemangiosarcoma 3 (5%)
Hemangiosarcoma, Multiple 1 (2%)
Hemangiosarcoma, Metastatic, Skin 1 (2%)
Hemangiosarcoma, Metastatic, Spleen 1 (2%) 1 (2%)
Hepatoblastoma 1 (2%)
Hepatocellular Carcinoma 6 (10%) 4 (7%) 13 (22%) 5 (8%) 8 (13%)
Hepatocellular Carcinoma, Multiple 1 (2%) 2 (3%)
Hepatocellular Adenoma 11 (18%) 5 (8%) 20 (33%) 7 (12%) 8 (13%)
Hepatocellular Adenoma, Multiple 17 (28%) 1 (2%) 5 (8%) 3 (5%)
Hepatocholangiocarcinoma 1 (2%)
Histiocytic Sarcoma 3 (5%) 1 (2%)
Ito Cell Tumor NOS, Multiple 1 (2%)
Hepatocyte, Hepatocellular Adenoma 1 (2%)
Mesentery (5) (1) (3) (3) (2)
Hemangiosarcoma 1 (33%)
Histiocytic Sarcoma 1 (50%)
Pancreas (60) (60) (60) (60) (60)
Stomach, Forestomach (60) (60) (60) (60) (60)
Mast Cell Tumor Benign 1 (2%)
Mast Cell Tumor Malignant 1 (2%)
Squamous Cell Papilloma 2 (3%) 1 (2%)
Page 8
NTP Experiment-Test: 05121-07 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05
Study Type: CHRONIC SCOPOLAMINE HYDROBROMIDE TRIHYDRATE Date: 04/03/96
Route: GAVAGE Time: 22:04:19
____________________________________________________________________________________________________________________________________
B6C3F1 MICE MALE 0 MG/KG 0 MG/KG 1 MG/KG 5 MG/KG 25 MG/KG
FEED RTD
____________________________________________________________________________________________________________________________________
ALIMENTARY SYSTEM - cont
Tooth (14) (4) (5) (2)
Odontoma 1 (7%) 1 (25%) 2 (40%) 1 (50%)
____________________________________________________________________________________________________________________________________
CARDIOVASCULAR SYSTEM
Heart (60) (60) (60) (60) (60)
Hemangiosarcoma, Metastatic, Spleen 1 (2%)
____________________________________________________________________________________________________________________________________
ENDOCRINE SYSTEM
Islets, Pancreatic (60) (60) (60) (60) (60)
Adenoma 3 (5%) 1 (2%) 1 (2%)
Pituitary Gland (58) (58) (56) (55) (53)
Pars Distalis, Adenoma 1 (2%)
Pars Intermedia, Adenoma 1 (2%) 1 (2%) 1 (2%)
Thyroid Gland (60) (60) (60) (60) (60)
Follicular Cell, Adenoma 1 (2%) 1 (2%) 1 (2%)
____________________________________________________________________________________________________________________________________
GENERAL BODY SYSTEM
None
____________________________________________________________________________________________________________________________________
GENITAL SYSTEM
Epididymis (60) (60) (60) (60) (60)
Hemangiosarcoma, Metastatic, Bone Marrow 1 (2%)
Preputial Gland (60) (60) (60) (59) (60)
Sarcoma 1 (2%)
Seminal Vesicle (60) (60) (60) (60) (60)
Adenoma 1 (2%)
Testes (60) (60) (60) (60) (60)
Interstitial Cell, Adenoma 1 (2%) 1 (2%)
____________________________________________________________________________________________________________________________________
HEMATOPOIETIC SYSTEM
Bone Marrow (60) (60) (60) (60) (60)
Hemangiosarcoma 1 (2%)
Hemangiosarcoma, Metastatic, Liver 1 (2%)
Hemangiosarcoma, Metastatic, Skin 1 (2%)
Hemangiosarcoma, Metastatic, Spleen 1 (2%)
Lymph Node (2) (1) (2) (3)
Bronchial, Carcinoma, Metastatic, Liver 1 (50%)
Page 9
NTP Experiment-Test: 05121-07 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05
Study Type: CHRONIC SCOPOLAMINE HYDROBROMIDE TRIHYDRATE Date: 04/03/96
Route: GAVAGE Time: 22:04:19
____________________________________________________________________________________________________________________________________
B6C3F1 MICE MALE 0 MG/KG 0 MG/KG 1 MG/KG 5 MG/KG 25 MG/KG
FEED RTD
____________________________________________________________________________________________________________________________________
HEMATOPOIETIC SYSTEM - cont
Mediastinal, Carcinoma, Metastatic, Liver 1 (50%)
Mediastinal, Histiocytic Sarcoma 1 (33%)
Lymph Node, Mandibular (59) (59) (58) (57) (56)
Lymph Node, Mesenteric (58) (53) (56) (56) (57)
Carcinoma, Metastatic, Liver 1 (2%)
Hemangiosarcoma, Metastatic, Spleen 1 (2%)
Histiocytic Sarcoma 3 (5%) 1 (2%)
Spleen (60) (60) (60) (60) (60)
Hemangiosarcoma 1 (2%) 1 (2%)
Hemangiosarcoma, Multiple 1 (2%)
Hemangiosarcoma, Metastatic, Liver 1 (2%)
Hemangiosarcoma, Metastatic, Skin 1 (2%)
Histiocytic Sarcoma 2 (3%) 1 (2%)
Thymus (51) (55) (54) (50) (50)
Carcinoma, Metastatic, Liver 1 (2%)
Mediastinum, Hemangioma 1 (2%)
____________________________________________________________________________________________________________________________________
INTEGUMENTARY SYSTEM
Skin (60) (60) (60) (60) (60)
Mast Cell Tumor Malignant 1 (2%)
Subcutaneous Tissue, Hemangiosarcoma 1 (2%)
____________________________________________________________________________________________________________________________________
MUSCULOSKELETAL SYSTEM
None
____________________________________________________________________________________________________________________________________
NERVOUS SYSTEM
None
____________________________________________________________________________________________________________________________________
RESPIRATORY SYSTEM
Lung (60) (60) (60) (60) (60)
Alveolar/Bronchiolar Adenoma 13 (22%) 10 (17%) 7 (12%) 7 (12%) 6 (10%)
Alveolar/Bronchiolar Adenoma, Multiple 1 (2%) 1 (2%) 2 (3%) 1 (2%)
Alveolar/Bronchiolar Carcinoma 2 (3%) 1 (2%) 4 (7%) 1 (2%) 2 (3%)
Alveolar/Bronchiolar Carcinoma, Multiple 1 (2%)
Carcinoma, Metastatic, Harderian Gland 2 (3%)
Carcinoma, Metastatic, Liver 1 (2%)
Hepatocellular Carcinoma, Metastatic, Liver 3 (5%) 2 (3%) 3 (5%) 1 (2%) 3 (5%)
Histiocytic Sarcoma 1 (2%) 1 (2%)
Nose (60) (60) (60) (60) (60)
Page 10
NTP Experiment-Test: 05121-07 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05
Study Type: CHRONIC SCOPOLAMINE HYDROBROMIDE TRIHYDRATE Date: 04/03/96
Route: GAVAGE Time: 22:04:19
____________________________________________________________________________________________________________________________________
B6C3F1 MICE MALE 0 MG/KG 0 MG/KG 1 MG/KG 5 MG/KG 25 MG/KG
FEED RTD
____________________________________________________________________________________________________________________________________
RESPIRATORY SYSTEM - cont
Mast Cell Tumor Malignant 2 (3%) 1 (2%)
____________________________________________________________________________________________________________________________________
SPECIAL SENSES SYSTEM
Harderian Gland (20) (18) (20) (21) (16)
Adenoma 3 (15%) 1 (6%) 1 (5%) 1 (5%) 2 (13%)
Carcinoma 4 (20%) 1 (5%) 1 (6%)
____________________________________________________________________________________________________________________________________
URINARY SYSTEM
Kidney (60) (60) (60) (60) (60)
Histiocytic Sarcoma 1 (2%)
Artery, Hepatocellular Carcinoma, Metastatic,
Liver 1 (2%)
Renal Tubule, Adenoma 1 (2%)
Renal Tubule, Carcinoma 2 (3%)
Urinary Bladder (60) (60) (60) (60) (59)
____________________________________________________________________________________________________________________________________
SYSTEMIC LESIONS
Multiple Organs *(60) *(60) *(60) *(60) *(60)
Histiocytic Sarcoma 3 (5%) 1 (2%)
Leukemia Lymphocytic 1 (2%) 1 (2%) 1 (2%)
Lymphoma Malignant Lymphocytic 1 (2%) 1 (2%) 3 (5%)
Lymphoma Malignant Mixed 3 (5%) 3 (5%) 2 (3%) 1 (2%)
____________________________________________________________________________________________________________________________________
* Number of animals with any tissue examined microscopically
Page 11
NTP Experiment-Test: 05121-07 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05
Study Type: CHRONIC SCOPOLAMINE HYDROBROMIDE TRIHYDRATE Date: 04/03/96
Route: GAVAGE Time: 22:04:19
____________________________________________________________________________________________________________________________________
B6C3F1 MICE MALE 0 MG/KG 0 MG/KG 1 MG/KG 5 MG/KG 25 MG/KG
FEED RTD
____________________________________________________________________________________________________________________________________
TUMOR SUMMARY
Total Animals with Primary Neoplasms (b) 47 26 45 32 31
Total Primary Neoplasms 73 36 70 44 39
Total Animals with Benign Neoplasms 40 20 32 22 19
Total Benign Neoplasms 52 24 38 27 21
Total Animals with Malignant Neoplasms 17 11 25 16 16
Total Malignant Neoplasms 20 12 32 17 18
Total Animals with Metastatic Neoplasms 4 4 5 4 3
Total Metastatic Neoplasm 6 5 6 10 4
Total Animals with Malignant Neoplasms
Uncertain Primary Site
Total Animals with Neoplasms Uncertain-
Benign or Malignant 1
Total Uncertain Neoplasms 1
____________________________________________________________________________________________________________________________________
a Number of animals examined microscopically at site and number of animals with lesion
b Primary tumors: all tumors except metastatic tumors
Page 12
------------------------------------------------------------
---------- END OF REPORT ----------
------------------------------------------------------------